ALK

Allergy solutions for life

Take back control

More than 500 million people worldwide have allergies. Many of them suffer in silence because the way ahead is too confusing.

allergy_solutions_for_life

News

  • Post date
    09/02/2019
    Germany becomes first launch market for ALK’s tree SLIT-tablet
  • Post date
    08/30/2019
    Report on transactions with ALK-Abelló A/S B-shares and associated securities by managerial staff
  • Post date
    08/13/2019
    Six-month interim report (Q2) 2019
  • Post date
    08/12/2019
    ALK upgrades its full-year financial outlook due to strong growth
  • Post date
    08/09/2019
    ALK announces new epinephrine auto-injector strategy based on innovative new product for the USA
  • Post date
    08/06/2019
    Release date of six-month interim report (Q2) 2019 for ALK and audio cast
  • Post date
    06/24/2019
    ALK submits registration application for tree SLIT-tablet in Canada
  • Post date
    06/07/2019
    ALK obtains European approval for its tree SLIT-tablet against allergic rhinitis
  • Post date
    06/04/2019
    As ALK prepares to further extend their SLIT-tablet portfolio, tablet formulation is seen as key in delivering consistent positive clinical trial results
ALK launches growth strategy
Transformational strategy to redefine ALK's position in the global allergy market and stimulate a new era of growth for the company.
Call for applicants
Scientists are invited to apply for the ARIA-EUFOREA Henning Løwenstein Research Award 2019.

ALK in brief

Allergy at a glance
Allergic rhinitis - popularly known as hay fever - is a widespread chronic disease. It is estimated to affect one in four persons in the industrialised world.
Our solutions
By collecting information and the latest and most trusted solutions together in one place, we want to make allergy surprisingly simple to manage.
Our heritage
Since 1923, we have consistently devised and developed major advances for the treatment of allergy. In recent years, we have invested substantially in the research and development of new, evidence-based allergy immunotherapy treatments.
Our responsibility
We aim to operate in a sustainable and ethical manner across our business and we underpin these aims with a range of policies and commitments.